Searchable abstracts of presentations at key conferences on calcified tissues

ba0006p146 | (1) | ICCBH2017

Stature and longitudinal growth in glucocorticoid naive boys with Duchenne Muscular Dystrophy

Joseph S , Edwards G , DiMarco M , Abu-Arafeh I , Baxter A , Horrocks I , McWilliams K , Naismith K , Stephen E , Ahmed S F , Wong S C

Background: Previous studies with small number of boys with Duchenne Muscular Dystrophy (DMD) suggest that growth failure occurs in glucocorticoid naïve (GC) boys.Objective: To evaluate height and longitudinal growth in boys with DMD prior to GC.Method: Retrospective evaluation in boys with DMD with height measurements obtained for clinical purposes. Out of the 91 boys currently managed in Scotland, 51 had at least one height ...

ba0007p71 | (1) | ICCBH2019

Necessity of high dose and prolonged duration denosumab post stem cell transplant for TNFRSF11A osteoclast-poor autosomal recessive osteopetrosis

Taylor-Miller Tashunka , Doss Hemalatha , Weerdenburg Heather , Whiting Sam , Sivaprakasam Ponni , Gassass Adam , Smithson Sarah F , Steward Colin G , Burren Christine P

Background: Hypercalcaemia is a risk following stem cell transplant (SCT) for all types of autosomal recessive osteopetrosis (ARO) due to restored osteoclast differentiation. This can be particularly severe in the osteoclast-poor (OP) form involving the tumour necrosis factor receptor superfamily 11A (TNFRSF11A) gene, encoding RANK. Denosumab, a monoclonal antibody blocking RANK activation, has been described for refractory post-SCT hypercalcaemia in two cases. Our case adds n...

ba0003pp278 | Osteoporosis: pathophysiology and epidemiology | ECTS2014

Fluoride exposure accelerates the development of postmenopausal osteoporosis: animal model

Kakei Mitsuo , Sakae Toshiro , Mishima Hiroyuki , Yoshikawa Masayoshi

Using ovariectomized rats as an animal model of postmenopausal women, we examined the causal relationship between fluoride (F) exposure and the high risk of development of osteoporosis. In order to obtain the estrogen (Es) deficient animals, 5-week-old Sprague–Dawley rats, which were overiectomized at 3- and the 5-week-old female rats without ovariectomy were purchased. The overiectomized rats were divided into two groups: the Es deficient, and the combination of Es defic...

ba0005ht5 | (1) | ECTS2016

Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study

Langdahl B , Libanati C , Crittenden D B , Bolognese M A , Brown J P , Daizadeh N S , Dokoupilova E , Engelke K , Finkelstein J S , Genant H K , Goemaere S , Hyldstrup L , Jodar-Gimeno E , Keaveny T M , Kendler D , Lakatos P , Maddox J , Malouf J , Massari F E , Molina J F

STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or TPTD for 12 months in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy (NCT01796301). This study enrolled women with postmenopausal osteoporosis who had taken an oral bisphosphonate for ≥3 years prior to screening and alendronate in the year prior to screening; had a BMD T-score ≤−2.5 at the total hip (TH), lumbar spine (LS), or femoral neck (FN);...

ba0003ht2 | (1) | ECTS2014

Osteoblast-specific ablation of p38α blunts the bone anabolic activity of parathyroid hormone

Thouverey Cyril , Caverzasio Joseph

Intermittent PTH administration (iPTH) increases bone mass in humans and animals. PTH exerts its effects by binding to PTH type 1 receptor (PTHR1) predominantly expressed in osteoblasts, resulting in activation of multiple downstream signaling pathways. In vitro investigations have suggested that p38 mitogen-activated protein kinase (MAPK) signaling is an important mediator of PTH-induced osteoblast functions.To evaluate the contribution of p38a...

ba0003pp324 | Osteoporosis: treatment | ECTS2014

The effects of risk factors on raloxifene, alendronate, and vitamin D treatment in postmenopausal osteoporosis

Somekawa Yoshiaki , Fusegi Atsusi , Okamoto Chiaki , Sekigawa Kana , Tsugata Mikiko , Umeki Hidenori

Objective: The purpose of this study was to compare the efficacy of raloxifene (RLX) 60 mg daily, vitamin D (VD) 200 IU daily, and alendronate (ALN) 35 mg once weekly on bone mineral density (BMD) of lumbar spine (L) and total femur (F) in postmenopausal women with osteoporosis, and the effects of the osteoporosis risk factors on BMDs and these treatments.Design and methods: The subjects were 242 postmenopausal Japanese women aged 48–87 years (mean ...

ba0002oc17 | Diagnostics | ICCBH2013

Determinants of bone mineral density in long-term adult survivors of childhood cancer

Klap B C , te Winkel M L , den Hoed M , van Waas M , Neggers S J C M M , Boot A M , Pieters R , Pluijm S M F , van den Heuvel-Eibrink M M

Objectives: Osteopenia is a complication of childhood cancer treatment but it is unknown to which extend this occurs in adult survivors, and which subgroups are at risk. We examined bone mineral density (BMD) and assed the relative importance of potential determinants of low BMD in very long-term adult survivors of childhood cancer.Methods: The single-center cohort study included 410 adult CCSs (median age at diagnosis: 6.6 years (range: 0–17 years)...

ba0004op12 | (1) | ICCBH2015

A non-invasive method for screening vitamin D insufficiency for adolescents using skin colourimetry

Lam Tsz Ping , Lee Wayne Y W , Cheung Franco T F , Tsang Echo K L , Wong Lyn L N , Lee Simon K M , Ng Bobby K W , Cheng Jack C Y

Introduction: Effective screening for vitamin D (Vit-D) insufficiency is desirable. Pigmentation of unexposed (constitutive) skin and exposed (facultative) skin can be measured with skin colourimetry to assess dermal capability in synthesizing Vit-D and degree of sunlight exposure respectively. This study aimed at evaluating whether skin colourimetry could be used to screen Vit-D insufficiency among adolescents.Methods: 240 healthy adolescents (mean age=...

ba0005oc1.4 | Clinical trials and osteoporosis treatment | ECTS2016

Relationship between total hip (TH) BMD T-score and incidence of nonvertebral fracture (NVFX) with up to 10 years of Denosumab (Dmab) treatment

Ferrari S , Adami S , Brown J P , Cosman F , Czerwiński E , de Gregorio L H , Malouf J , Reginster J-Y , Daizadeh N S , Wang A , Wagman R B , Lewiecki E M

The relationship between BMD T-score and FX risk has not been established in patients receiving osteoporosis therapy. In the FREEDOM Extension study, continuous DMAb therapy for up to 10 years increased BMD levels with no therapeutic plateau at lumbar spine or TH [Bone et al, ASBMR 2015]. Such improvements would only be meaningful if associated with FX reductions. We investigated the relationship between TH BMD T-score and NVFX in women who received DMAb during FREEDOM and tho...

ba0007oc9 | (1) | ICCBH2019

Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial

Ward Leanne M , Alos Nathalie , Cabral David A , Rodd Celia , Sbrocchi Anne Marie , Padidela Raja , Shaw Nick , Kostik Mikhail , Alexeeva Ekaterina , Thandrayen Kebashni , Aftring Paul , Choudhury Anup , Sunkara Gangadhar , Sayyed Sarfaraz , Munns Craig F.

Objectives: We evaluated the efficacy and safety of intravenous zoledronic acid (IV ZA) in children with glucocorticoid-induced osteoporosis (GIOP) through a randomized, placebo (PBO)-controlled trial.Methods: In this multi-national Phase 3 trial (NCT00799266), children 5–17 years of age with GIOP and low-trauma vertebral fractures (VF) were randomized 1:1 to IV ZA 0.05 mg/kg or IV PBO every six months for one year. Changes in lumbar spine areal bon...